Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MEN1 | O00255 | 1/20 | 0.80 |
| ▸ | LMNA | P02545 | 1/20 | 0.80 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.80 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.80 |
| ▸ | NEU1 | Q99519 | 1/20 | 0.62 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Oseltamivir SCHEMBL32035 | 0.92 | MEN1 (0.88) | MEN1LMNACYP3A4KMT2ANEU1 | |
| Oseltamivir SCHEMBL14775954 | 0.92 | MEN1 (0.88) | MEN1LMNACYP3A4KMT2ANEU1 | |
| Oseltamivir SCHEMBL19513553 | 0.92 | MEN1 (0.88) | MEN1LMNACYP3A4KMT2ANEU1 | |
| Oseltamivir SCHEMBL4234896 | 0.92 | MEN1 (0.88) | MEN1LMNACYP3A4KMT2ANEU1 | |
| Oseltamivir SCHEMBL13459830 | 0.92 | MEN1 (0.88) | MEN1LMNACYP3A4KMT2ANEU1 | |
| Oseltamivir SCHEMBL14283136 | 0.92 | MEN1 (0.88) | MEN1LMNACYP3A4KMT2ANEU1 | |
| Oseltamivir SCHEMBL125557 | 0.92 | MEN1 (0.88) | MEN1LMNACYP3A4KMT2ANEU1 | |
| Oseltamivir SCHEMBL18379765 | 0.92 | MEN1 (0.88) | MEN1LMNACYP3A4KMT2ANEU1 | |
| Oseltamivir SCHEMBL2319265 | 0.92 | MEN1 (0.83) | MEN1LMNACYP3A4KMT2ANEU1 | |
| SCHEMBL974858 | 0.92 | MEN1 (0.67) | MEN1LMNACYP3A4KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2702990-A1 | ANTIARRHYTHMIC DRUG, ATRIAL FIBRILLATION INHIBITOR, MODEL OF SUSTAINED ATRIAL FIBRILLATION AND METHOD FOR PRODUCING SAME, AND METHOD FOR SCREENING ATRIAL FIBRILLATION INHIBITOR | Toho University (JP) | 2014-03-05 | — | — | EP | disclosed |
| US-20140051756-A1 | METHOD FOR PREVENTING OR TREATING ARRHYTHMIA, METHOD FOR PREVENTING OR TREATING ATRIAL FIBRILLATION, MODEL OF SUSTAINED ATRIAL FIBRILLATION, METHOD FOR PRODUCING THE MODEL, AND METHOD FOR SCREENING FOR ATRIAL FIBRILLATION INHIBITOR | TOHO UNIVERSITY (JP) | 2014-02-20 | — | — | US | disclosed |
| US-8304553-B2 | Method of forming oseltamivir and derivatives thereof | NANYANG TECHNOLOGICAL UNIVERSITY (SG) | 2012-11-06 | — | — | US | disclosed |
| US-20110021762-A1 | METHOD OF FORMING OSELTAMIVIR AND DERIVATIVES THEREOF | NANYANG TECHNOLOGICAL UNIVERSITY (SG) | 2011-01-27 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140051756-A1 | METHOD FOR PREVENTING OR TREATING ARRHYTHMIA, METHOD FOR PREVENTING OR TREATING ATRIAL FIBRILLATION, MODEL OF SUSTAINED ATRIAL FIBRILLATION, METHOD FOR PRODUCING THE MODEL, AND METHOD FOR SCREENING FOR ATRIAL FIBRILLATION INHIBITOR | UGGT1, GUSB, KCNH1 | MEN1 3864/4885LMNA 1043/4885CYP3A4 192/4885 |
| US-20110021762-A1 | METHOD OF FORMING OSELTAMIVIR AND DERIVATIVES THEREOF | AOC1, ALK, ALDH3A1 | MEN1 4561/4885LMNA 3294/4885CYP3A4 26/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.